Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.

Oncotarget - 6 Oct 2015

Di Paolo Daniela, Yang D, Pastorino Fabio, Emionite Laura, Cilli Michele, Daga Antonio, Destafanis Elisa, Di Fiore Annarita, Piaggio Francesca, Brignole Chiara, Xu Xiaobao, Liang Chris, Gibbons James, Ponzoni Mirco, Perri Patrizia

Abstract excerpt

Many different aberrations in the Anaplastic Lymphoma Kinase (ALK) were found to be oncogenic drivers in several cancers including neuroblastoma (NB), therefore ALK is now considered a critical player in NB oncogenesis and a promising therapeutic target. The ALK-inhibitor crizotinib has a limited activity against the various ALK mutations identified in NB patients. We tested: the activity of the novel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Biological Availability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Half-Life

Share to Liposomes

Share to Nanoparticles

Share to Neuroblastoma

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 26299615
DOI: 10.18632/oncotarget.4342
PMCID: PMC4745691

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.PMID 26299615Read ↗

Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.Semantic proximity Read ↗

Targeted Therapy for Neuroblastoma: ALK InhibitorsSemantic proximity Read ↗

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatmentSemantic proximity Read ↗

ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside.Semantic proximity Read ↗

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.Semantic proximity Read ↗

Natural Killer–Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape MechanismsSemantic proximity Read ↗

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.Semantic proximity Read ↗

Oncogenic mutations of ALK in neuroblastoma.Semantic proximity Read ↗

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical ModelsSemantic proximity Read ↗

Evaluating the effects of aging on biodistribution and gene silencing activity of lipid-siRNA conjugates delivered into cerebrospinal fluidSemantic proximity Read ↗

Expanding the Reach of RNAi Therapeutics with Next Generation Lipophilic siRNA ConjugatesSemantic proximity Read ↗

Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft ModelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.